Spondyloarthritis

Comparing Burden of Psoriatic Arthritis With Different Definitions of Disease Activity

Comparing Burden of Psoriatic Arthritis With Different Definitions of Disease Activity

By

Researchers aimed to compare the disease burden of patients with psoriatic arthritis with low disease activity according to 2 definitions.

Clinical Features Identified in Enthesitis-Related Juvenile Idiopathic Arthritis, Juvenile Spondyloarthritis

Clinical Features Identified in Enthesitis-Related Juvenile Idiopathic Arthritis, Juvenile Spondyloarthritis

By

Results confirm that juvenile spondyloarthritis is characterized by its peripheral pattern at disease onset, with peripheral arthritis and enthesitis.

Etanercept Monotherapy vs Combination Therapy Examined in Psoriatic Arthritis

Etanercept Monotherapy vs Combination Therapy Examined in Psoriatic Arthritis

By

Etanercept in combination with a conventional synthetic DMARD did not substantially improve clinical response compared with etanercept monotherapy in patients with psoriatic arthritis.

Radiographic Sacroiliitis vs MRI Structural Lesions for Axial Spondyloarthritis Classification

Radiographic Sacroiliitis vs MRI Structural Lesions for Axial Spondyloarthritis Classification

By

Researchers sought to investigate the utility of adding structural MRI lesions of the sacroiliac joints to the imaging criterion of the ASAS axSpA criteria.

Sustained Clinical, Functional Improvements With Adalimumab in Axial Spondyloarthritis

Sustained Clinical, Functional Improvements With Adalimumab in Axial Spondyloarthritis

By

Results from the ABILITY-1 study show sustained clinical and functional improvements with adalimumab treatment in nonradiographic axial spondyloarthritis.

Apremilast Monotherapy Effective for DMARD-Naive Psoriatic Arthritis

Apremilast Monotherapy Effective for DMARD-Naive Psoriatic Arthritis

By

The PALACE 4 trial found that apremilast monotherapy improved symptoms and was generally well-tolerated in DMARD-naive psoriatic arthritis.

Secukinumab Administered by Autoinjector Safe, Effective in Psoriatic Arthritis

Secukinumab Administered by Autoinjector Safe, Effective in Psoriatic Arthritis

By

Results from the FUTURE 3 study show that administration of secukinumab by autoinjector resulted in sustained improvements at 52 weeks in patients with active psoriatic arthritis.

Disease Activity in Axial Spondyloarthritis Generally Low, Stable During Pregnancy

Disease Activity in Axial Spondyloarthritis Generally Low, Stable During Pregnancy

By

Researchers found that disease activity was highest during the second trimester of pregnancy.

Trabecular Bone Score May Predict Future Vertebral Fracture in Axial Spondyloarthritis

Trabecular Bone Score May Predict Future Vertebral Fracture in Axial Spondyloarthritis

By

Researchers found that trabecular bone scores may be predictive of future vertebral fractures in patients with axial spondyloarthritis.

Secukinumab Improves Symptoms, Inhibits Radiographic Progression in Psoriatic Arthritis

Secukinumab Improves Symptoms, Inhibits Radiographic Progression in Psoriatic Arthritis

By

The results of the FUTURE 5 study show that secukinumab improved signs and symptoms and inhibited radiographic structural progression at 24 weeks in psoriatic arthritis.

TNF Inhibitors Reduce Long-Term Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis

TNF Inhibitors Reduce Long-Term Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis

By

TNFi therapy yielded favorable results in patients with AS or PsA, with progressively better responses between 4 months and 3 years.

Dual Neutralization of IL-17A, IL-17F With Bimekizumab Suppresses PsA Joint Inflammation

Dual Neutralization of IL-17A, IL-17F With Bimekizumab Suppresses PsA Joint Inflammation

By

Dual inhibition of IL-17A and IL-17F with bimekizumab suppresses joint inflammation in patients with psoriatic arthritis.

Examining Progression From Inflammatory Back Pain to Spondyloarthritis

Examining Progression From Inflammatory Back Pain to Spondyloarthritis

By

Less than one-third of patients with new-onset inflammatory back pain were found to progress to spondyloarthritis during a 13-year period, while most resolved to inflammatory back pain.

Thickened Pulleys in PsA Support Deep Koebnerization in Dactylitis

Thickened Pulleys in PsA Support Deep Koebnerization in Dactylitis

By

The accessory pulleys linked to the flexor tendons are thicker in patients with psoriatic arthritis.

Comorbid Fibromyalgia and Axial Spondyloarthritis: Response to TNF Blocker Therapy

Comorbid Fibromyalgia and Axial Spondyloarthritis: Response to TNF Blocker Therapy

By

Researchers sought to confirm whether concomitant fibromyalgia has a negative effect on TNF blocker response.

Adalimumab Reduces Whole-Body MRI Indices of Inflammation in axSpA

Adalimumab Reduces Whole-Body MRI Indices of Inflammation in axSpA

By

Adalimumab may decrease whole-body magnetic resonance imaging indices of inflammation in both axial and peripheral joints and enthuses in axSpA.

Anti-CD74 Antibodies Have Limited Diagnostic Value in Early Axial Spondyloarthritis

Anti-CD74 Antibodies Have Limited Diagnostic Value in Early Axial Spondyloarthritis

By

Anti-CD74 IgG and IgA antibodies have limited value in the diagnosis of early axial spondyloarthritis in younger patients who present with early back pain.

Adherence to Anti-TNF Blocker Recommendations in axSpA Linked to Improved Quality of Life

Adherence to Anti-TNF Blocker Recommendations in axSpA Linked to Improved Quality of Life

By

Adherence to recommendations for the initiation and continuation of TNF-alpha blocker therapy in patients with axial spondyloarthritis is associated with improved quality of life.

Capsule Endoscopy Superior to Colonoscopy for Detection of Crohn Disease in Spondyloarthritis

Capsule Endoscopy Superior to Colonoscopy for Detection of Crohn Disease in Spondyloarthritis

By

Capsule endoscopy was superior to standard colonoscopy for the detection of Crohn disease in patients with spondyloarthritis.

Early Response in Psoriatic Arthritis Treatment Predicts Long-Term Outcomes

Early Response in Psoriatic Arthritis Treatment Predicts Long-Term Outcomes

By

Initial response to psoriatic arthritis therapy has a predictive value of long-term outcomes as early as 3 months after treatment initiation.

TNF Inhibitor Response in Women vs Men With Ankylosing Spondylitis

TNF Inhibitor Response in Women vs Men With Ankylosing Spondylitis

By

Investigators evaluated sex differences in the effectiveness of tumor necrosis factor inhibitors in patients with ankylosing spondylitis.

Challenges of Targeting Remission in Axial Spondyloarthritis

Challenges of Targeting Remission in Axial Spondyloarthritis

By

Current guidelines define remission as the absence of clinical and laboratory evidence of significant inflammatory disease, but the tools that are currently available are inadequate to assess clinical remission.

Patients With PsA Achieve Early, Sustained Minimal Disease Activity With Secukinumab

Patients With PsA Achieve Early, Sustained Minimal Disease Activity With Secukinumab

By

Results from the FUTURE 2 study show that patients with PsA who were treated with secukinumab achieved early and sustained minimal disease activity over 2 years of therapy.

High Coronary Plaque Burden Is Independent of Metabolic Syndrome in Psoriatic Arthritis

High Coronary Plaque Burden Is Independent of Metabolic Syndrome in Psoriatic Arthritis

By

Psoriatic arthritis is associated with accelerated coronary plaque formation, particularly mixed plaques, independent of metabolic disease.

Increased HLA-B27 Associated With More Severe Sonographic Enthesitis in PsA

Increased HLA-B27 Associated With More Severe Sonographic Enthesitis in PsA

By

In patients with psoriatic arthritis, increasing levels of HLA-B27 are associated with more severe sonographic enthesitis.

Functional Status in Early Axial Spondyloarthritis: The Role of Spinal Structural Damage

Functional Status in Early Axial Spondyloarthritis: The Role of Spinal Structural Damage

By

Results of the GESPIC study found that structural damage in the spine and disease activity were both determinants of functional status and spine mobility in patients with early axial spondyloarthritis.

Sustained Reduction in axSpA Joint Inflammation With Certolizumab Pegol

Sustained Reduction in axSpA Joint Inflammation With Certolizumab Pegol

By

Decreases in spinal and sacroiliac joint inflammation on MRI were maintained through 204 weeks with certolizumab pegol treatment.

Spondyloarthritis Increases Risk for Dysrhythmias and Aortic Regurgitation

Spondyloarthritis Increases Risk for Dysrhythmias and Aortic Regurgitation

By

The risk for aortic regurgitation and cardiac rhythm abnormalities was evaluated in a nationwide cohort of patients with spondyloarthritis.

Efficacy and Safety of Ixekizumab Evaluated in Active Psoriatic Arthritis

Efficacy and Safety of Ixekizumab Evaluated in Active Psoriatic Arthritis

By

Results from the phase 3 SPIRIT-P1 study show that treatment with ixekizumab every 2 or 4 weeks in patients with active psoriatic arthritis demonstrated sustained efficacy and a favorable safety profile.

Efficacy of Apremilast Monotherapy Assessed in Biologic-Naive Psoriatic Arthritis

Efficacy of Apremilast Monotherapy Assessed in Biologic-Naive Psoriatic Arthritis

By

Patients with psoriatic arthritis who are taking apremilast experienced early symptom relief and sustained clinical improvement through 1 year of treatment.

Sign Up for Free e-newsletters